newsfilter
← Earnings
Earnings Releases·

Relay Therapeutics — Third Quarter 2026 Earnings Summary

  • Revenue for the nine months ended September 30, 2026, was $3.35 million, a decrease from $8.36 million in the prior year period, while Q3 2026 revenue remained at $0; net loss for Q3 2026 was $81.7 million ($0.37 per share) compared to $74.1 million ($0.43 per share) in Q3 2025.
  • Cash, cash equivalents, and investments totaled $848.6 million as of September 30, 2026, with management confirming this position is sufficient to fund operating expenses and capital requirements into 2029.
  • The Phase 3 ReDiscover-2 trial enrollment is estimated to complete in mid-2027, approximately one year faster than benchmarks, with a regulatory update on the first-line endocrine-sensitive breast cancer trial design expected by year-end 2026.
  • Shannon Campbell joined as Head of Commercial to lead preparations for zovegalisib, following the December 2024 licensing of lirafugratinib to Elevar Therapeutics, which received full FDA approval for cholangiocarcinoma.
Company
RELAY THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology